Free Submission Public Relations & NewsPR-inside.com
Home
Deutsch English

Finance
Therapeutic Class Report Overview - Hemophilia

Therapeutic Class Report Overview - Hemophilia - new market research report published


Print article Print article
© companiesandmarkets.com

companiesandmarkets.com
companiesandmarkets.com
2014-03-14 08:27:01 - Therapeutic Class Report Overview - Hemophilia - a new market research report on companiesandmarkets.com

Hemophilia is an inherited (X-linked recessive trait), lifelong bleeding disorder that prevents blood from clotting due to insufficient or lack of adequate amount of clotting factors - Factor VIII (FVIII) and Factor IX (proteins in blood that control bleeding).

Plasma-derived FVIII and FIX proteins were used in the 70´s for treating these disorders but transmission of contaminating viruses reduced its use. In 1999, recombinant FVIIIs and FIX, free of viral, animal, or human proteins became the standard of care (SoC). However, frequent injections used for prophylaxis resulted in development of antibodies (called inhibitors - acquired hemophilia or neutralizing abs) to FVIII or FIX. The presence of inhibitors complicated treatment of hemophilia A and B- ~30% in hemophilia A and up to

 

 

3 to 5% in hemophilia B pts. The high cost of treatment, frequent dosing, and infusion related adverse events are other concerns.

To address these limitations, companies are developing next generation clotting factors which are more potent - Short Acting or Long Acting Recombinant Factors. These potentially could result in fewer injections, reduce the inhibitor level, and improve compliance. Several of these pipeline products are now poised for approval and launch in the next two-three years. At present, Baxter, Bayer/ CSL, Pfizer, Novo Nordisk dominate the current ~$10b hemophilia market. In this report, we have analyzed the clinical efficacy, safety, and commercial prospects of the late-stage products in development and expect the long acting products that have best clinical and safety data to lead by offering patients better Cost per Quality Adjusted Life Year (QALY).

Click for report details: www.companiesandmarkets.com/Market/Healthcare-and-Medical/Market ..

Browse all Healthcare and Medical Market Research Reports www.companiesandmarkets.com/Market/Healthcare-and-Medical/Market ..

Browse all Healthcare and Medical Company Profile Reports www.companiesandmarkets.com/Market/Healthcare-and-Medical/Compan ..

Browse all Latest Market Research Reports www.companiesandmarkets.com/Market/All/Market-Research?aCode=f3f ..

About Us
Companiesandmarkets.com is a leading online business information aggregator with over 300,000 market reports and company profiles available to our clients. Our extensive range of reports are sourced from the leading publishers of business information and provide clients with the widest range of information available. In terms of company profiles, Companiesandmarkets.com’s online database allows clients access to market and corporate information to over 100,000 different companies. We provide clients with a fully indexed database of information where clients can find specific market reports on their niche industry sectors of interest.


Author:
Mike King
e-mail
Web: www.companiesandmarkets.com
Phone: London: +44 (0) 203 086 8600

Disclaimer: If you have any questions regarding information in these press releases please contact the company added in the press release. Please do not contact pr-inside. We will not be able to assist you. PR-inside disclaims contents contained in this release.
Latest News
Read the Latest News
www.newsenvoy.com

 


Terms & Conditions | Privacy | About us | Contact PR-inside.com